[144] Disc Medicine, Inc. SEC Filing

Rhea-AI Filing Summary

Disc Medicine, Inc. (IRON) filed a Form 144 indicating a proposed sale of 53,215 common shares through Merrill Lynch. At the most recent market price used in the filing, the shares are valued at $3.23 million. The filing lists total shares outstanding at 34,634,295, so the planned sale represents roughly 0.15 % of outstanding stock, a modest proportion that limits potential market impact.

The seller acquired the stock on 05 May 2020 via a private placement for cash. In the past three months related entities—Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P.—sold a combined 1,848 shares for gross proceeds of $112,964. The anticipated sale date for the new block is 23 July 2025, and the shares are expected to be sold on the Nasdaq exchange.

Positive

• Sale represents only ~0.15 % of shares outstanding, suggesting minimal dilution and limited potential impact on the float.

Negative

• Insider/affiliate intends to liquidate $3.23 M in stock, which could introduce modest selling pressure and signal reduced insider exposure.

Insights

Securities Analyst

TL;DR: Small insider block (0.15 %) worth $3.2 M slated for 7/23/25; limited dilution but indicates liquidity event.

The Form 144 signals that Atlas-affiliated funds intend to sell 53,215 IRON shares via Merrill Lynch. Given the company’s 34.6 M shares outstanding, the planned disposition is immaterial from a dilution standpoint and unlikely to pressure prices significantly under normal trading volumes. Nonetheless, insider sales can be interpreted as profit-taking or portfolio rebalancing. Investors may monitor whether the transaction completes as scheduled and whether further filings follow.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch One Bryant Park New York NY 10036	53215	3232279.10	34634295	07/23/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	05/01/2020	Private Placement	Issuer			53215	05/01/2020	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Atlas Venture Fund X, L.P. 300 Technology Sq Ste 8 Cambridge MA 02139	Common Stock	07/18/2025	1184	72375.20
Atlas Venture Opportunity Fund I, LP. 300 Technology Sq Ste 8 Cambridge MA 02139	Common Stock	07/18/2025	664	40588.80

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Disc Medicine (IRON) shares are covered by this Form 144?

The notice covers 53,215 common shares.

What is the aggregate market value of the shares to be sold?

The filing lists an aggregate market value of $3,232,279.10.

When is the approximate sale date for the shares?

The filer expects to sell the shares on 23 July 2025.

What percentage of Disc Medicine’s outstanding shares does this sale represent?

About 0.15 % of the 34,634,295 shares outstanding.

Which broker will handle the transaction?

The shares are to be sold through Merrill Lynch, One Bryant Park, New York.